SPOTLIGHT: Actavis receives warning letter

The FDA has issued a warning letter regarding Actavis' manufacturing facility in Little Falls, NJ. The agency has questioned its reporting of adverse medical events and raised questions regarding the marketing status of older products. No new products will be made there until the agency's concerns are satisfied. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.